Molecular phenotyping for neurodegenerative diseases
We are developing a targeted mass-spectrometry biomarker tool for differentiating subgroups of patients with Parkinsonian disorders exhibiting similar clinical symptoms but having distinct molecular etiologies of neurological disease.
